The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 15, 2019
Filed:
Jan. 26, 2015
Applicant:
Children's Hospital of Eastern Ontario Research Institute Inc., Ottawa, CA;
Inventors:
Robert G. Korneluk, Ottawa, CA;
Eric C. Lacasse, Ottawa, CA;
Shawn T. Beug, Ottawa, CA;
Vera A. Tang, Ottawa, CA;
Assignee:
Children's Hospital of Eastern Ontario Research Institute Inc., Ottawa, ON, CA;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/427 (2006.01); A61K 39/12 (2006.01); A61K 31/40 (2006.01); A61K 39/39 (2006.01); A61K 35/766 (2015.01); A61K 45/06 (2006.01); A61K 31/404 (2006.01); A61K 31/4745 (2006.01); A61K 35/765 (2015.01); A61K 38/21 (2006.01); A61K 35/761 (2015.01); A61K 31/407 (2006.01); A61K 31/409 (2006.01); A61K 31/433 (2006.01); A61K 31/55 (2006.01); A61K 39/00 (2006.01); A61K 39/205 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 31/404 (2013.01); A61K 31/407 (2013.01); A61K 31/409 (2013.01); A61K 31/427 (2013.01); A61K 31/433 (2013.01); A61K 31/4745 (2013.01); A61K 31/55 (2013.01); A61K 35/761 (2013.01); A61K 35/765 (2013.01); A61K 35/766 (2013.01); A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 39/0011 (2013.01); A61K 39/205 (2013.01); A61K 45/06 (2013.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55588 (2013.01); A61K 2039/55594 (2013.01); A61K 2039/572 (2013.01); A61K 2039/585 (2013.01); C12N 2760/20134 (2013.01);
Abstract
The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.